Obesity SURMOUNT-1 Trial In adults with obesity (without diabetes): Tirzepatide (15 mg) : 20.9% average body weight reduction over 72 weeks Semaglutide (2.4 mg) (based on STEP trials): ~14.9% average reduction STEP 5 Long-Term Results Semaglutide also demonstrated durable effects: At 104 weeks, patients maintained ~15% weight loss on semaglutide 2.4 mg (STEP 5) SELECT Trial Cardiovascular Benefit Semaglutide significantly reduced major adverse cardiovascular events by 20% in people with obesity and pre-existing heart diseaseindicating benefit beyond weight loss
Whereas, L-carnosine works to preserve cellular health and maintain many normal bodily functions
Exenatide-loaded TDDS have shown enhanced skin permeation, improved long-term storage stability, sustained blood concentrations for up to 48 hours, increased bioavailability, rapid reduction of blood glucose levels, and suppression of food intake in experimental studies
Youve likely heard the buzzthe whispers about a robust peptide protocol that can transform everything from your skin to your gut health
van BloemendaalLTen KulveJSla FleurSEIjzermanRGDiamantM
Quick Decision Guide Need medication immediately